Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Pugazhendhi Vijayaraman

EP · Geisinger

View

Dr. Felix Yang

EP · NYU Langone

View

Dr. Gregory Marcus

EP · UCSF

View

Dr. Miguel Leal

EP · Emory University Hospital

View

Dr. Chirag Barbhaiya

EP · NYU

View

Dr. William Sauer

EP · BWH

View

Dr. Dorairaj Prabhakaran

General Cardiology

View

Dr. Trey Woods

General Cardiology · Emory Healthcare

View

Dr. Brahmajee Nallamothu

Interventional Cardiology · UMHS

View

Dr. Jennifer Rymer

Interventional & Peripheral Cards · Duke University

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Value of Left Ventricular Low Voltage Area and Ejection Fraction in Predicting End-Stage Heart Failure Outcomes After Ventricular Tachycardia Ablation in Patients With Non-Ischemic Cardiomyopathy.

    Oct 8, 2026DOI: 10.1161/circep.126.014886Journal ArticleAHA

    Written by: Arian AfzalianAlireza OraiiCorentin ChaumontOriol Rodriguez-QueraltoYuichiro SagawaCarli J PetersErica ZadoBalaram Krishna J HanumanthuPoojita ShivamurthyTimothy M MarkmanMatthew C HymanCory M TschabrunnGustavo GuandaliniAndres EnriquezFermin C GarciaMichael P RileyDavid LinRobert D SchallerSaman NazarianDavid J CallansGregory E SuppleRamanan KumareswaranSanjay DixitDavid S FrankelFrancis E Marchlinski

    Find these authors on Roon

    RS
    Dr. Robert Schaller
    EP · HUP

    Summary

    BACKGROUND: Patients with nonischemic cardiomyopathy (NICM) and ventricular tachycardia are at increased risk for adverse HF outcomes, and abnormal left ventricular (LV) substrate identified by endocardial unipolar and bipolar low-voltage areas (LVAs) may aid in risk stratification. This study assessed the association of LV unipolar and bipolar LVAs with end-stage HF outcomes in patients with NICM undergoing ventricular tachycardia ablation.METHODS: Patients with NICM and LV ejection fraction (EF) <50% undergoing ventricular tachycardia ablation from 2019 to 2023 were included. Endocardial voltage mapping defined confluent (>2 cm2) unipolar LVAs as <8.27 mV and bipolar LVAs as <1.5 mV during sinus or paced rhythm. End-stage HF outcomes included HF death, LV assist device implantation, or heart transplant. Multivariable Cox proportional hazards regression analysis assessed associations between unipolar/bipolar LVAs and end-stage HF outcomes.RESULTS: One hundred eleven patients with NICM (mean age, 64.6±9.8 years; 81.1% male; mean LVEF, 33.8±11.7%) were included. During a median follow-up of 28.1 months (interquartile range, 18-46), 28 (25.2%) patients experienced end-stage HF outcomes. Unipolar LVA (hazard ratio, 1.03 per 1% increase [95% CI, 1.01-1.05]; P=0.002) and LVEF (hazard ratio, 1.04 per 1% decrease [95% CI, 1.00-1.09]; P=0.03) were independently associated with higher end-stage HF risk, while bipolar LVA was not (hazard ratio, 0.98, 1% increase [95% CI, 0.96-1.01]; P=0.25). A 3-point risk score based on the Youden index, unipolar LVA ≥70% (2 points), 35% to 70% (1 point), and LVEF ≤25% (1 point), had 82.1% sensitivity and 77.1% specificity for predicting end-stage HF in scores ≥2.CONCLUSIONS: In patients with NICM undergoing ventricular tachycardia ablation, unipolar LVA and LVEF are independent predictors of end-stage HF outcomes. Integrating these predictors yields a prognostic score to identify patients at the highest risk of end-stage HF outcomes.
    RSDr. Robert Schaller
    Leading Voice

    Dr. Robert Schaller

    Cardiology · Cardiac Electrophysiology
    Hospital of the University of Pennsylvania
    robertschaller
    Philadelphia, PA, USA